Mirum Pharmaceuticals, Inc.
NASDAQ:MIRMBiotechnology
+$3.89 today
- Market cap
- $6.04B
- Beta
- 0.51
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$13.57
Volume 0.50M
Average 0.95M
MIRM Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Mirum Pharmaceuticals, Inc.NASDAQ: MIRM
Accounts Payables · Q2 FY2026 · quarter ended Jun 2026
Accounts payables growth accelerates
Q2 FY2026 accounts payables of $38.18M rose 261.0% year over year, ahead of the +177.5% change in trailing-twelve-month accounts payables. Sequentially, it fell 33.3% from the prior quarter. Over 3 fiscal years it compounded at +87.2% a year.
Context
- Accounts payables amounted to 9.6% of revenue in FY2025, down 2.4 pp from a year earlier.
- Accounts payables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +261.0% holds above the trailing-twelve-month pace of +177.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 50.1M USD
- Year-over-year change
- +24.3%
- 4-year CAGR
- +21.9%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 50.1M | +24.3% |
| FY2024 | 2024-12-31 | 40.31M | +31.0% |
| FY2023 | 2023-12-31 | 30.78M | +302.9% |
| FY2022 | 2022-12-31 | 7.64M | -66.3% |
| FY2021 | 2021-12-31 | 22.66M | — |
Accounts Payables vs competitors
How MIRM compares with its peers on the latest reported figures
- MIRM's LTM Jun 2026 accounts payables of $123.22M is the largest of the 8 companies compared; the peer median is $399K.
- Its year-over-year change of +177.5% is the 2nd highest of 8, against a peer median of +116.9%.
- Accounts payables amounts to 19.9% of revenue for MIRM, versus a peer median of 0.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $123.22M | +177.5% | +87.2% | 19.9% | |
| LTM Mar 2026 | $15.45M | +166.8% | -33.0% | 2.3% | |
| LTM Jun 2026 | $6.65M | -122.9% | +29.1% | 0.5% | |
| LTM Sep 2026 | $2.72M | +151.1% | — | 0.4% | |
| LTM Mar 2026 | $2.19M | -26.1% | -1.7% | 4.8% | |
| LTM Mar 2026 | $453K | +116.9% | -3.3% | 1258.3% | |
| LTM Mar 2026 | $426K | -118.1% | -20.2% | 0.6% | |
| LTM Mar 2026 | $399K | +1230.0% | -34.4% | 0.6% | |
| Peer median (excluding MIRM) | $399K | +116.9% | -11.7% | 0.6% | |
Competitors are the stored peer set for MIRM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (83.99M) | (135.67M) | (163.42M) | (87.94M) | (23.36M) |
| Depreciation & Amortization | 975K | 3.24M | 10.83M | 23.63M | 24.24M |
| Deferred Income Tax | 595K | (6.58M) | 0 | 0 | 0 |
| Stock-Based Compensation | 23.09M | 27.01M | 35.02M | 48.44M | 71.42M |
| Change in Working Capital | 16.98M | (21.05M) | (22.64M) | 22.59M | (19.72M) |
| Accounts Receivables | 0 | (20.73M) | (43.97M) | (11.43M) | (48.06M) |
| Inventory | (495K) | (3.45M) | (4.39M) | (3.17M) | (8.45M) |
| Accounts Payables | 22.66M | 7.64M | 30.78M | 40.31M | 50.1M |
| Other Working Capital | (5.18M) | (4.51M) | (5.05M) | (3.13M) | (13.32M) |
| Other Non-Cash Items | (90.41M) | 12.91M | 69.26M | 3.6M | 3.24M |
| Operating Cash Flow | (132.76M) | (120.14M) | (70.94M) | 10.33M | 55.83M |
| Capital Expenditures | (19.02M) | (278K) | (20.11M) | (993K) | (954K) |
| Acquisitions (Net) | (19M) | (7.98M) | (212.76M) | 0 | 0 |
| Purchases of Investments | (198.03M) | (132.32M) | (27.33M) | (89.03M) | (97.43M) |
| Sales of Investments | 157.6M | 140.3M | 153M | 19.89M | 74.43M |
| Other Investing Activities | 127M | 7.98M | (20M) | (20M) | 0 |
| Investing Cash Flow | 48.55M | 7.7M | (107.2M) | (90.13M) | (23.95M) |
| Debt Repayment | 0 | 0 | 305.3M | 0 | 0 |
| Common Stock Issued | 6.91M | 107.37M | 216.68M | 17.7M | 40.14M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 66.55M | 1.72M | (185.39M) | 0 | 0 |
| Financing Cash Flow | 73.47M | 109.09M | 336.6M | 17.7M | 40.14M |
| Effect of Forex Changes | (1K) | 12K | (133K) | (1.3M) | 3.22M |
| Net Change in Cash | (10.75M) | (3.34M) | 158.32M | (63.4M) | 75.24M |
| Free Cash Flow | (151.78M) | (120.41M) | (91.05M) | 9.33M | 54.87M |
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
Intrinsic Alpha fair value
Locked
Current Price
$92.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.